Cipla launches Afrezza, India's 1st inhaled insulin
Cipla just launched Afrezza, India's first inhaled insulin since Exubera was withdrawn in 2007, making diabetes care less stressful for millions.
Approved last December, this fast-acting powder (from MannKind) lets people manage their blood sugar without needles—a big relief for over 10 crore adults living with diabetes.
How it works & Cipla's plan
Using Afrezza is pretty straightforward: pick a cartridge, pop it into the inhaler, breathe in through your mouth, and toss the used cartridge.
Cipla has exclusive marketing rights in India.
What to know before trying
Afrezza comes in single-use cartridges that dissolve quickly when you inhale.
It isn't recommended if you have asthma or serious lung issues like COPD.
This is the first inhaled insulin available here since Exubera was pulled from shelves back in 2007 due to safety concerns—so it's a pretty big step forward for diabetes care in India.